In the present study, we have shown that the combination of S-1 (or 5FU) and EGFR-targeted therapy results in a synergistic antitumor effect in EGFR-amplified GC cells, but not in those lacking EGFR amplification. This evidence concerns the gene EGFR and gastric cancer.